Published : Apr-2020
No. of Pages : 204
1.1 List of Tables
1.2 List of Figures
2 Age-Related Macular Degeneration: Executive Summary
2.1 AMD Market Will More than Double in Size, Reaching Sales of $18.7B in 2028
2.2 Fast Track Designation for Anti-GA and Anti-dAMD Agents Will Expand Treatment Options for Underserved Patient Populations
2.3 Longer-Acting Anti-VEGF Therapies Are Needed to Improve Patient Compliance Rates
2.4 Six Late-Stage Pipeline Agents Are Set to Generate More than $1B in Annual Sales by 2028
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Overview
4.1.2 Etiology
4.1.3 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
5.4.4 Total Prevalent Cases of AMD by Laterality
5.4.5 Total Prevalent Cases of Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
5.4.6 Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
5.5 Epidemiological Forecast for AMD, 2018-2028
5.5.1 Total Prevalent Cases of AMD
5.5.2 Age-Specific Total Prevalent Cases of AMD
5.5.3 Sex-Specific Total Prevalent Cases of AMD
5.5.4 Total Prevalent Cases of AMD by Laterality
5.5.5 Total Prevalent Cases of Early AMD
5.5.6 Total Prevalent Cases of Late AMD
5.5.7 Total Prevalent Cases of Late Dry AMD
5.5.8 Total Prevalent Cases of Late Wet AMD
5.5.9 Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
5.5.10 Diagnosed Prevalent Cases of AMD
5.5.11 Age-Specific Diagnosed Prevalent Cases of AMD
5.5.12 Sex-Specific Diagnosed Prevalent Cases of AMD
5.5.13 Diagnosed Prevalent Cases of Early AMD
5.5.14 Diagnosed Prevalent Cases of Late AMD
5.5.15 Diagnosed Prevalent Cases of Late Dry AMD
5.5.16 Diagnosed Prevalent Cases of Late Wet AMD
5.5.17 Diagnosed Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines
6.2.2 Treating Late AMD
6.3 US
6.4 5EU
6.5 Asia-Pacific
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Lack of Therapies for GA and dAMD
8.3 Longer-Acting Anti-VEGF Therapies
8.4 Timely Diagnosis of Patients with Early and Intermediate AMD
8.5 Less Invasive Drug Formulations
9 Pipeline Assessment
9.1 Overview
9.2 Late-Stage Pipeline Products
9.3 Innovative Early Stage Approaches
10 Current and Future Players
11 Market Outlook
12 Appendix
List of Tables
Table 1: AMD: Key Metrics in the 9MM
Table 2: Biological Pathways Associated with AMD Risk Genes
Table 3: The Four-Stage AREDS Classification of AMD
Table 4: Symptoms of AMD
Table 5: Risk Factors and Comorbidities for AMD
Table 6: Treatment Guidelines for AMD
Table 7: AMD Disease Management - US
Table 8: AMD Disease Management - 5EU
Table 9: AMD Disease Management - Asia-Pacific Region
Table 10: Marketed Drugs for AMD in the 9MM, 2020
Table 11: Comparison of Therapeutic Classes in Development for AMD, 2018-2028
Table 12: Innovative Early-Stage Approaches for AMD
Table 13: Roche/Genentech's AMD Portfolio Assessment, 2020
Table 14: Novartis' AMD Disease Portfolio Assessment, 2020
Table 15: Regeneron's AMD Portfolio Assessment, 2020
Table 16: Bayer's AMD Portfolio Assessment, 2020
Table 17: Chengdu Kanghong AMD Portfolio Assessment, 2020
Table 18: Allergan's AMD Disease Portfolio Assessment, 2018
Table 19: Apellis' AMD Portfolio Assessment, 2018
Table 20: Alkeus Pharma's AMD Portfolio Assessment, 2020
Table 21: Dobecure's AMD Portfolio Assessment, 2020
Table 22: Gene Techno Science's AMD Portfolio Assessment, 2020
Table 23: Outlook Therapeutics' AMD Portfolio Assessment, 2020
Table 24: MacuCLEAR's AMD Portfolio Assessment, 2020
Table 25: AMD Market - Global Drivers and Barriers, 2018-2028
Table 26: Key Events Impacting Sales for AMD in the US, 2018-2028
Table 27: AMD Market - Drivers and Barriers in the US, 2018-2028
Table 28: Key Events Impacting Sales for AMD in the 5EU, 2018-2028
Table 29: AMD Market - Drivers and Barriers in the 5EU, 2018-2028
Table 30: Key Events Impacting Sales for AMD in Japan, 2018-2028
Table 31: AMD Market - Drivers and Barriers in Japan, 2018-2028
Table 32: Key Events Impacting Sales for AMD in China, 2018-2028
Table 33: AMD Market - Global Drivers and Barriers in China, 2018-2028
Table 34: Key Events Impacting Sales for AMD in Australia, 2018-2028
Table 35: AMD Market - Global Drivers and Barriers in Australia, 2018-2028
Table 36: Key Historical and Projected Launch Dates for AMD
Table 37: Key Historical and Projected Patent Expiry Dates for AMD
Table 38: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global (9MM) Sales Forecast, by Country, for AMD in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in AMD During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of AMD During the Forecast Period
Figure 4: Anatomy of the Eye and Macula: Healthy Eyes, dAMD, and wAMD
Figure 5: 9MM, Total Prevalence of AMD, Men and Women, Ages ?50 Years, %, 2018
Figure 6: 9MM, Diagnosed Prevalence of AMD, Men and Women, Ages ?50 Years, 2018
Figure 7: 9MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
Figure 8: 9MM, Sources Used to Forecast the Total Prevalent Cases of AMD by Laterality
Figure 9: 9MM, Sources Used to Forecast the Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD and Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD
Figure 10: 9MM, Total Prevalent Cases of AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 11: 9MM, Total Prevalent Cases of AMDby Age, Both Sexes, N, 2018
Figure 12: 9MM, Total Prevalent Cases of AMD, by Sex, Ages ?50 Years, N, 2018
Figure 13: 9MM, Total Prevalent Cases of AMD by Laterality, Ages ?50 Years, Both Sexes, N, 2018
Figure 14: 9MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 15: 9MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 16: 9MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 17: 9MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 18: 9MM, Total Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 19: 9MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 20: 9MM, Diagnosed Prevalent Cases of AMD by Age, Both Sexes, N, 2018
Figure 21: 9MM, Diagnosed Prevalent Cases of AMD, by Sex, Ages ?50 Years, N, 2018
Figure 22: 9MM, Diagnosed Prevalent Cases of Early AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 23: 9MM, Diagnosed Prevalent Cases of Late AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 24: 9MM, Diagnosed Prevalent Cases of Late Dry AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 25: 9MM, Diagnosed Prevalent Cases of Late Wet AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 26: 9MM, Diagnosed Prevalent Cases of Geographic Atrophy Secondary to Late Dry AMD, Both Sexes, Ages ?50 Years, N, 2018
Figure 27: Amsler Grid, as Viewed by Patients with Normal Vision and with wAMD
Figure 28: Unmet Needs and Opportunities in AMD
Figure 29: ETDRS Chart Used to Measure Visual Acuity
Figure 30: Overview of the Development Pipeline in AMD
Figure 31: Ongoing Phase II/III Trials for Anti-VEGF Pipeline Agents in Development for AMD in the 9MM
Figure 32: Ongoing Phase II/III Trials for Pipeline Agents in Development for AMD in the 9MM
Figure 33: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of AMD During the Forecast Period
Figure 34: Company Portfolio Gap Analysis in AMD, 2018-2028
Figure 35: Clinical Trials for AMD in the 9MM by Trial Status
Figure 36: Global (9MM) Sales Forecast by Country for AMD in 2018 and 2028
Figure 37: Global (9MM) Sales Forecast by Disease Subtype in 2028
Figure 38: Global (9MM) Sales Forecast for GA in 2028
Figure 39: Global (9MM) Sales Forecast for dAMD in 2028
Figure 40: Global (9MM) Drug Sales for wAMD in 2018 and 2028
Figure 41: US Sales Forecast by Disease Subtype in 2028
Figure 42: US Sales Forecast for GA in 2028
Figure 43: wAMD Sales in the US by Drug, 2018 and 2028
Figure 44: 5EU Sales Forecast by Disease Subtype in 2028
Figure 45: wAMD Sales in the 5EU by Drug, 2018 and 2028
Figure 46: wAMD Sales in Japan by Drug, 2018 and 2028
Figure 47: wAMD Sales in China by Drug, 2018 and 2028
Figure 48: Sales Forecast by Disease Subtype in Australia in 2028
Figure 49: wAMD Sales in Australia by Drug, 2018 and 2028
